Supreme Court Ties On FDA Pre-Emption; Congress Seeks To Resolve Issue
This article was originally published in The Tan Sheet
Executive Summary
Citing a crisis within FDA, members of Congress are demanding that the agency withdraw its proposed rule to limit when drug and device manufacturers can revise their product labeling without prior FDA approval
You may also be interested in...
Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy
The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: It will not have any real impact on industry. The bad news: It will not matter because pre-emption in the drug arena already took a body blow in the Supreme Court's Wyeth v. Levine ruling
Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy
The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: It will not have any real impact on industry. The bad news: It will not matter because pre-emption in the drug arena already took a body blow in the Supreme Court's Wyeth v. Levine ruling
Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy
The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: It will not have any real impact on industry. The bad news: It will not matter because pre-emption in the drug arena already took a body blow in the Supreme Court's Wyeth v. Levine ruling